Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.50 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2642010 | 0.85 | HTT (0.44) | HTTFGFR1SRC | |
| SCHEMBL8329072 | 0.85 | CYP17A1 (0.59) | HTTFGFR1SRC | |
| SCHEMBL18226399 | 0.85 | FGFR1 (0.47) | HTTFGFR1 | |
| SCHEMBL17739633 | 0.84 | NPC1 (0.42) | HTTFGFR1 | |
| SCHEMBL19350758 | 0.84 | MKNK1 (0.46) | HTTFGFR1 | |
| SCHEMBL8327896 | 0.80 | CYP17A1 (0.44) | HTTFGFR1 | |
| SCHEMBL31608474 | 0.80 | HTT (0.49) | HTT | |
| Oxalic Acid SCHEMBL2642016 | 0.80 | FGFR1 (0.42) | HTTFGFR1SRC | |
| SCHEMBL8329895 | 0.79 | ALDH1A1 (0.52) | HTTFGFR1 | |
| SCHEMBL8329068 | 0.78 | HTT (0.43) | HTTFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240052418-A1 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-15 | — | — | US | disclosed |
| US-11814681-B2 | Method for predicting a subjects response to SLC modulator therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220216426-A1 | NITROGEN-CONTAINING COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| US-20210254158-A1 | METHOD FOR PREDICTING A SUBJECTS RESPONSE TO SLC MODULATOR THERAPY | RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. | 2021-08-19 | — | — | US | disclosed |
| WO-2021135182-A1 | NITROGEN-CONTAINING COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS | 陕西莱特光电材料股份有限公司 | 2021-07-08 | — | — | WO | disclosed |
| US-11041207-B2 | Method for predicting a subject's response to valproic acid therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-06-22 | — | — | US | disclosed |
| WO-2021068755-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2021-04-15 | — | — | WO | disclosed |
| WO-2019046303-A1 | A METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20150140123-A1 | Protein expression analyses for identifying genotoxic compounds | MERCK PATENT GMBH (DE) | 2015-05-21 | — | — | US | disclosed |
| US-20090134028-A1 | Method of Estimating Effect of Test Chemical on Living Organisms | CHEMICALS EVALUATION AND RESEARCH INSTITUTE (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7399857-B2 | Synthesis of organometallic cyclometallated transition metal complexes | EASTMAN KODAK COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| US-20060224007-A1 | Synthesis of organometallic cyclometallated transition metal complexes | EASTMAN KODAK COMPANY | 2006-10-05 | — | — | US | disclosed |
| US-20060223997-A1 | Synthesis of organometallic cyclometallated transition metal complexes | EASTMAN KODAK COMPANY | 2006-10-05 | — | — | US | disclosed |
| WO-2003087099-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087099-A1 | IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223997-A1 | Synthesis of organometallic cyclometallated transition metal complexes | IMMT, AP3M1, AP1M1 | HTT 1911/4885FGFR1 3387/4885SRC 966/4885 |
| US-20220216426-A1 | NITROGEN-CONTAINING COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS | NCL, DNMT3A, NUDT1 | HTT 248/4885FGFR1 3962/4885SRC 3221/4885 |
| US-20060224007-A1 | Synthesis of organometallic cyclometallated transition metal complexes | IMMT, AP3M1, AP1M1 | HTT 1911/4885FGFR1 3387/4885SRC 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.